Valneva Investors Brace for Q1 Results as Legal Investigation and Vaccine Doubts Mount

The French vaccine developer Valneva heads into Wednesday’s first-quarter earnings release under a cloud of legal scrutiny and clinical disappointment, after a law firm launched a probe into potential securities law violations. Shares slid nearly 7% on Tuesday to €2.57, extending a punishing run that has wiped out more than a third of the stock’s value since the start of the year.

The investigation by Pomerantz, a US-based plaintiffs’ firm, centres on a 23 March announcement in which Valneva and partner Pfizer hailed Phase 3 data for their Lyme disease vaccine candidate. The shot failed to meet its primary efficacy endpoint, a miss the companies attributed to an unexpectedly low number of reported cases. The disclosure triggered a 37% rout in Valneva’s American depositary receipts and has now drawn legal attention. Officials have not yet filed a suit, but the probe adds a fresh layer of uncertainty to a story already weighed down by weak near-term fundamentals.

Analyst opinions on the stock are now sharply divided. Goldman Sachs has downgraded Valneva to “Sell” and slashed its price target to €2.15, citing heavy operating losses, a negative gross margin, and the unpredictable path to regulatory approval for the Lyme vaccine. At the other end of the spectrum, Jefferies maintains a “Buy” rating with a $15 target, while Guggenheim remains optimistic and expects the company to report first-quarter revenue above the Street consensus – Guggenheim’s own estimate stands at roughly €49 million, compared with the average analyst projection of €44.9 million.

Should investors sell immediately? Or is it worth buying Valneva?

The consensus calls for a 9% year-on-year drop in quarterly sales to €44.9 million. The bottom line is expected to show a loss per share of €0.07, slightly wider than the €0.06 loss in the same period of 2025. For the full year, the analyst community forecasts revenue of €165.7 million and a per-share loss of €0.41. Management has guided for 2026 sales between €155 million and €170 million, with growth in Valneva’s proprietary vaccine portfolio offset by a decline in third-party manufacturing contracts.

Technically, the stock is trading about 21% below its 50-day moving average of €3.24 and has lost roughly 32% since January. From last year’s 52-week high of €5.16, the decline exceeds 50%. The relative strength index stands at 56, suggesting a neutral posture with no immediate trigger for either a recovery or another leg down. Clear downside emerges below €2.03, a support level that could be tested if Wednesday’s numbers fall short of expectations.

A rare piece of encouraging news arrived on Tuesday, when the European Parliament and Council reached a deal on the Critical Medicines Act. The legislation aims to reduce the bloc’s dependence on imported vaccines by favouring domestic production and adopting a “Buy European” approach in public procurement. For Valneva, which manufactures its own shots in Europe, the act could open new opportunities over the medium term. In the short run, however, it does little to address the pressing questions around liquidity and the timeline for the Lyme vaccine’s potential approval.

Wednesday’s report will therefore be scrutinised not only for sales and profit figures but also for any update on cash runway and the regulatory submission path for the Lyme programme. With the legal probe still in its early stages and a widening rift between bulls and bears on Wall Street, Valneva needs a clean quarter to steady investor confidence. A miss on the top or bottom line could accelerate the slide toward the support zone, while a beat – particularly one that validates Guggenheim’s more optimistic outlook – might give the beaten-down stock a much-needed reprieve.

Ad

Valneva Stock: New Analysis - 13 May

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69318243 |